Targeting the molecular signatures that define dysfunctional brain circuits
Precision pharmacology, grounded in the brain’s own biology
Brain disorders arise from dysfunction in specific molecular systems and specific circuits. Yet most CNS drugs act broadly across the brain, causing side effects, abuse risk, or complicated delivery without addressing the underlying pathology.
We take a different approach. We define our targets by receptor subtypes and their regionally enriched support proteins, designing small molecules to modulate pathological signaling where it originates, while preserving healthy brain function.
NeuroVectrix: Computational Discovery Built for the Brain
NeuroVectrix Discovery Autopilot campaign: a coordinating agent delegates lead optimization & SAR analysis to specialized agents, returning a prioritized list of compounds for synthesis & testing.
NeuroVectrix is our in-house computational discovery engine. It combines generative chemistry, predictive modeling, and structure–activity analysis in a closed loop with our proprietary cell-based assays, so every new experimental result improves the next round of compound design. Built for the challenges of CNS drug discovery, NeuroVectrix is accelerating optimization of our lead program and extending our precision approach to new circuits and indications.
Structure Viewer
Pose Viewer
Activity Cliff Analysis
NL-101: our lead program in PTSD
NL-101 selectively modulates AMPA receptors containing GluA1 and the auxiliary protein TARPγ4, demonstrating how receptor composition and auxiliary protein association can be exploited to target pathological signaling in the amygdala. It is a non-hallucinogenic small molecule.
Conventional CNS drugs
Act broadly across the brain, driving side effects, abuse risk, and tolerability limits.
NL-101
Designed to act only where pathological signaling originates, preserving healthy brain function.
Illustrative comparison.
Latest News
-
Neurovation Labs Receives o2h Kickstarter Award to Advance Precision Neurotherapeutics
October 9, 2026
-
Precision Medicine Platform Targets Specific Brain Region to Treat PTSD with Dr. Jennifer Perusini Neurovation Labs
February 19, 2026
-
Beyond Psychedelics: The Next Generation of Precision Neurotherapeutics
January 2, 2026
CEO Dr. Jennifer Perusini joined "The Rush Hour" broadcast on Spectrum News NY1 to discuss research aimed at helping veterans with PTSD
“It’s not just psychological anymore…it’s really biological underpinnings that we’re looking at, so those defense mechanisms in the brain, those ones that are important for survival and those fear circuits are really in overdrive and they’re just stuck in the ‘on’ position. So that’s what we’re trying to target.”
